Identification of Pivotal ceRNA Networks Associated with Stanford-A Aortic Dissection via Integrated Bioinformatics Analysis.

Yuyuan Hu, Zhenhao Liu, Yan Qin, Nan Wu, Tao Yang, Xinmeng Cheng, Chunyan Wang, Xuening Wang
Author Information
  1. Yuyuan Hu: Department of Cardiac Surgery, the First Affiliated Hospital of Shandong Second Medical University, Weifang, 261000, People's Republic of China.
  2. Zhenhao Liu: Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences Tongji Shanxi Hospital, Taiyuan, 030032, People's Republic of China.
  3. Yan Qin: Department of Science and Technology Education, Shanxi Center for Clinical Laboratory, Taiyuan, 030012, People's Republic of China. ORCID
  4. Nan Wu: Department of Cardiac Surgery, Shanxi Provincial People's Hospital, Fifth Hospital of Shanxi Medical University, Taiyuan, 030012, People's Republic of China.
  5. Tao Yang: Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences Tongji Shanxi Hospital, Taiyuan, 030032, People's Republic of China.
  6. Xinmeng Cheng: Department of Cardiovascular Surgery, the Affiliated Cardiovascular Hospital of Shanxi Medical University and Shanxi Cardiovascular Hospital (Institute), Taiyuan, Shanxi, 030000, People's Republic of China.
  7. Chunyan Wang: Department of Clinical Laboratory, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030013, People's Republic of China. ORCID
  8. Xuening Wang: Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences Tongji Shanxi Hospital, Taiyuan, 030032, People's Republic of China.

Abstract

Objective: Stanford-A Aortic dissection (TAAD) is a rare and fatal disease, genetic factors remains poorly known. Study has confirmed that lncRNA play an important role in various physiological and pathological processes. This study attempts to elucidate the underlying molecular mechanisms of TAAD through lncRNA-associated competitive endogenous RNA (ceRNA) networks.
Methods: In this study, aortic vascular of 5 TAAD and 5 control (ischemic heart disease) were subjected to lncRNA and mRNA microarray analysis, and differentially expressed mRNAs (DEGs) and differentially expressed lncRNAs (DELs) were identified. The differentially expressed miRNAs (DEmiR) were screened by GSE98770 dataset. The ceRNA network (lncRNA-miRNA-mRNA) was constructed by bioinformatics analysis. The accuracy of hub genes as biomarkers for predicting TAAD was evaluated by receiver operating characteristic (ROC) curve. Finally, the biomarkers were verified by assessing their mRNA levels using real-time quantitative PCR (RT-qPCR).
Results: This study revealed 161 DELs, 87 DEmiRs and 103 DEGs between TAAD and control. We constructed ceRNA networks based on the screened 1 lncRNA, 4 miRNAs and 7 mRNAs. We identified three lncRNA-miRNA-mRNA regulatory axes, namely the VCAN axis (LINC01355 - hsa-miR-186-5p / hsa-miR-30a-5p /hsa-miR-30c-5p - VCAN), LOX axis (LINC01355-hsa-miR-145-5p/hsa-miR-186-5p/ hsa-miR-30a-5p / hsa-miR-30c-5p - LOX), and CTSS axis (LINC01355 - hsa-miR-186-5p - CTSS) based on gene ontology, pathway enrichment and protein-protein interaction (PPI) network, which may play an important role in TAAD. The clinical performance of VCAN, CTSS, and LOX in TAAD diagnosis was evaluated, and the AUCs of VCAN, CTSS, and LOX were 0.920 (p<0.001), 0.880 (p=0.002) and 0.840 (p=0.011), respectively. Furthermore, mRNA expression of VCAN in human aortic tissue significantly overexpressed in the TAAD patients (p<0.001).
Conclusion: This study identifies three ceRNA interaction axes, especially VCAN associated with TAAD pathogenesis, providing fundamentals of bioinformatics for understanding the molecular mechanisms of TAAD pathogenesis and developing potential therapeutic strategies for TAAD.

Keywords

References

  1. J Proteome Res. 2016 Jan 4;15(1):38-47 [PMID: 26626371]
  2. Circ Res. 2019 Feb 15;124(4):619-630 [PMID: 30763215]
  3. Mol Med Rep. 2016 Jun;13(6):5005-12 [PMID: 27109786]
  4. Ann Cardiothorac Surg. 2016 Jul;5(4):389-96 [PMID: 27563553]
  5. EMBO Mol Med. 2024 Jan;16(1):132-157 [PMID: 38177536]
  6. Front Genet. 2022 Feb 08;13:781676 [PMID: 35211156]
  7. J Inflamm Res. 2021 Nov 09;14:5877-5890 [PMID: 34795497]
  8. Atherosclerosis. 2015 Aug;241(2):772-82 [PMID: 26058741]
  9. Cancer Med. 2020 Dec;9(24):9219-9235 [PMID: 33232580]
  10. Cardiovasc Diagn Ther. 2020 Aug;10(4):811-819 [PMID: 32968636]
  11. Scand Cardiovasc J. 2020 Feb;54(1):1-13 [PMID: 31542960]
  12. Arterioscler Thromb Vasc Biol. 2020 Sep;40(9):2054-2069 [PMID: 32640907]
  13. Front Cardiovasc Med. 2022 Apr 15;9:890607 [PMID: 35498004]
  14. J Atheroscler Thromb. 2018 Feb 1;25(2):111-123 [PMID: 28978867]
  15. Theranostics. 2022 Jan 1;12(2):910-928 [PMID: 34976220]
  16. Front Genet. 2022 Jan 25;12:755706 [PMID: 35145542]
  17. Swiss Med Wkly. 2017 Sep 05;147:w14489 [PMID: 28871571]
  18. JCI Insight. 2018 Mar 8;3(5): [PMID: 29515038]
  19. J Am Heart Assoc. 2020 Jan 7;9(1):e013803 [PMID: 31902328]
  20. Cell Physiol Biochem. 2017;41(5):1830-1837 [PMID: 28376483]
  21. Front Cell Dev Biol. 2021 Dec 06;9:792051 [PMID: 34938738]
  22. Front Cardiovasc Med. 2021 Jul 07;8:692856 [PMID: 34307505]
  23. Clin Pharmacol Ther. 2016 May;99(5):494-501 [PMID: 26910520]
  24. Mol Aspects Med. 2022 Dec;88:101106 [PMID: 35868042]
  25. J Med Biochem. 2019 May 11;38(3):268-275 [PMID: 31156336]
  26. J Cell Mol Med. 2020 Oct;24(20):11622-11637 [PMID: 32885591]
  27. J Vasc Res. 2013;50(1):1-10 [PMID: 23018968]
  28. Circulation. 2023 Sep 19;148(12):959-977 [PMID: 37555319]
  29. Biomed Res Int. 2019 Jul 14;2019:3629751 [PMID: 31380418]
  30. Cell Physiol Biochem. 2018;46(3):1027-1041 [PMID: 29669321]
  31. ESC Heart Fail. 2021 Jun;8(3):1840-1849 [PMID: 33713567]
  32. Cell Death Dis. 2019 Jun 26;10(7):502 [PMID: 31243265]
  33. Cell. 2013 Mar 14;152(6):1298-307 [PMID: 23498938]
  34. PLoS One. 2012;7(10):e48843 [PMID: 23119099]
  35. Eur Heart J. 2024 Jan 27;45(4):287-305 [PMID: 37992083]
  36. Eur Heart J. 2014 Nov 1;35(41):2873-926 [PMID: 25173340]
  37. Genome Biol. 2007;8(9):R183 [PMID: 17784955]
  38. Gastric Cancer. 2022 Jan;25(1):44-63 [PMID: 34247316]
  39. BMC Genomics. 2021 Oct 7;22(1):724 [PMID: 34620091]
  40. Int J Gen Med. 2021 Oct 16;14:6863-6873 [PMID: 34703291]
  41. Front Cardiovasc Med. 2021 Jul 02;8:680065 [PMID: 34277731]

Word Cloud

Created with Highcharts 10.0.0TAADVCANceRNA-lncRNAstudyLOXCTSSStanford-AaorticmRNAanalysisdifferentiallyexpressednetworkbioinformaticsaxis0Aorticdissectiondiseaseplayimportantrolemolecularmechanismsnetworks5controlmRNAsDEGsDELsidentifiedmiRNAsscreenedlncRNA-miRNA-mRNAconstructedbiomarkersevaluatedbasedthreeaxesLINC01355hsa-miR-186-5p/hsa-miR-30a-5pinteractionp<0001p=0pathogenesisObjective:rarefatalgeneticfactorsremainspoorlyknownStudyconfirmedvariousphysiologicalpathologicalprocessesattemptselucidateunderlyinglncRNA-associatedcompetitiveendogenousRNAMethods:vascularischemicheartsubjectedmicroarraylncRNAsDEmiRGSE98770datasetaccuracyhubgenespredictingreceiveroperatingcharacteristicROCcurveFinallyverifiedassessinglevelsusingreal-timequantitativePCRRT-qPCRResults:revealed16187DEmiRs103147regulatorynamely/hsa-miR-30c-5pLINC01355-hsa-miR-145-5p/hsa-miR-186-5p/hsa-miR-30c-5pgeneontologypathwayenrichmentprotein-proteinPPImayclinicalperformancediagnosisAUCs920880002840011respectivelyFurthermoreexpressionhumantissuesignificantlyoverexpressedpatientsConclusion:identifiesespeciallyassociatedprovidingfundamentalsunderstandingdevelopingpotentialtherapeuticstrategiesIdentificationPivotalNetworksAssociatedDissectionviaIntegratedBioinformaticsAnalysis

Similar Articles

Cited By